Delivery Order SPE2DB22D3301-SPE2DB25FY8PR
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for ENBREL 50 MG/ML SureClick auto-injectors valued at $9,253.56 on July 30, 2025, with a completion date of July 31, 2025. This firm fixed price, non-competitive delivery order represents pharmaceutical procurement for military healthcare needs and is being fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania, the company's corporate headquarters. This delivery order is...
- The Defense Logistics Agency (DLA) awarded a $35,072.01 delivery order to AmerisourceBergen Drug Corp for Enbrel 50 mg/mL SureClick auto-injectors, with an ultimate completion date of August 21, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The place of performance is listed...
- The Defense Logistics Agency awarded a delivery order valued at $46,236.88 to AmerisourceBergen Drug Corp for the supply of ENBREL 50 MG/ML SureClick auto-injectors. The contract, awarded on July 30, 2025, with an ultimate completion date of July 31, 2025, was competitively awarded with no set-aside designation and carries firm fixed pricing terms. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $10,276.74 for ENBREL 50 mg/mL SureClick auto-injectors on September 4, 2025, with completion scheduled for September 5, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. ENBREL is a biologic immunosuppressant used to treat rheumatoid arthritis, psoriasis, and...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $19,183.90 to AmerisourceBergen Drug Corp for the supply of Enbrel 50 mg/ml SureClick auto-injectors. This firm fixed-price delivery order, issued on August 5, 2025, with an ultimate completion date of August 6, 2025, represents a competitively awarded contract with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a major...
- The Defense Logistics Agency (DLA) awarded a $86,921.96 delivery order to AmerisourceBergen Drug Corp for ENBREL 50 mg/mL SureClick auto-injectors, effective August 21, 2025, with ultimate completion by August 22, 2025. This firm fixed-price contract was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $31,940.40 to AmerisourceBergen Drug Corp for ENBREL 50 mg/mL SureClick auto-injectors, with an ultimate completion date of August 26, 2025. This competitively awarded, firm fixed-price delivery order was issued with no set-aside designation and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. The contract supports the federal government's pharmaceutical procurement needs through AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,592.67 to AmerisourceBergen Drug Corp for the supply of ENBREL 50 mg/ml SureClick auto-injectors. This non-set-aside, competitively awarded contract was executed on July 21, 2025, with an ultimate completion date of July 22, 2025, and reflects a firm fixed price arrangement. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $67,548.68 firm fixed-price delivery order to AmerisourceBergen Drug Corp for ENBREL 50 mg/mL SureClick auto-injectors. The contract, which was competitively awarded with no set-aside designation, was executed on August 13, 2025, with an ultimate completion date of August 14, 2025. Performance will be conducted at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite...
- The Defense Logistics Agency (DLA) awarded a $30,241.74 delivery order to AmerisourceBergen Drug Corp for ENBREL 50 mg/ml SureClick auto-injectors, with an ultimate completion date of August 26, 2025. This firm fixed-price contract, awarded on August 25, 2025, represents a non-set-aside competitive award under the DLA's pharmaceutical procurement framework. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters...
- SPE2DB22D3301Indefinite Delivery Contract
- SPE2DB22D3301-SPE2DB25FY8PRDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $101,132.02 to AmerisourceBergen Drug Corp for the supply of ENBREL 50 mg/mL SureClick auto-injectors. This firm fixed price, competitively awarded contract was executed on July 31, 2025, with an ultimate completion date of August 1, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award carries no set-aside designation, reflecting AmerisourceBergen's competitive capability in federal pharmaceutical procurement. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the contractor to supply an extensive range of pharmaceutical products and medical supplies to military healthcare systems worldwide. ENBREL, a biologic immunosuppressant used in the treatment of rheumatoid arthritis and other autoimmune conditions, supports the Defense Health Agency and other federal healthcare systems' requirements for specialized medical commodities across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $101.1k | 7/31/25 |